BiomaterialsBioprintingPatentsWomen of 3D Printing

Dimension Inx granted U.S. patent for 3D-Painting System

The biofabrication platform is now patent-protected in Japan, Australia and the United States

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Chicago-based biofabrication company Dimension Inx has been granted a U.S. patent covering its 3D-Painting System, a platform built for designing and manufacturing next-gen biomaterials for organ and tissue repair and regeneration. The company says the patent issuance strengthens its position on the market by showcasing the differentiation of its biomaterials offering.

The biofabrication company was born out of biomaterials research pioneered by co-founders Ramille Shah, PhD, and Adam Jakus, PhD, at Northwestern University’s Tissue Engineering and Additive Manufacturing Lab. The pair developed a portfolio of biomaterials over nearly a decade before spinning off with Dimension Inx, which now holds exclusive worldwide rights to commercialize the 3D-Painting System and associated materials.

Dimension Inx’s now patent-protected 3D-Painting System is capable of high loading bioactive ingredients and rapid printing of biomaterials. Notably, the platform is designed to dry at room temperature, effectively eliminating the need for sintering—which can effect bioactivity—and other processing techniques like cross-linking. According to the company, these capabilities are “critical for conferring the necessary composition and microstructure of surgical implants that promote healing and tissue regeneration.”

The rapid printing rates of the 3D-Painting System also mean that the process is scalable and is suitable for commercial production of novel medical products.

Dimension Inx patent

“As we move toward the clinic with our first medical products, this patent strengthens the differentiation and defensibility of our biomaterials platform,” explained Caralynn Nowinski Collens, MD, CEO of Dimension Inx. “Further, it advances our mission of delivering regenerative medical products to the patients that need them by being the industry partner of choice for biomaterials design and production.”

The patent is U.S. Patent No. 10,584,254 “A Universal Method for Production and 3D-Printing of High-Particle-Content 3D-Inks,” and covers Dimension Inx’s compositions, materials and methods for producing and 3D printing high-particle-content 3D inks. Dimension Inx also hold similar patents in Japan (P6542807) and Australia (AU2015258978).

“The award of this patent recognizes the novelty and value of the 3D-Painting System,” said Dr. Jakus, CTO at Dimension Inx. “The innovation protected here overcomes hurdles faced by other 3D printing and bioprinting methods and enables, for the first time, the ability to create and rapidly 3D print an extensive range of biomaterials without heat or other processing techniques that limit or destroy bioactivity.”

Today, Dimension Inx’s biomaterials, including Hyperelastic Bone and 3D-Graphene & Graphite, can be purchased through one of its many partners, such as Advanced BioMatrix, Advanced Solutions Life Sciences, Allevi and Millipore Sigma.

Research
Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Save
Accept all Services

Newsletter

Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.